ANALISIS EFEKTIVITAS DAN BIAYA ENOXAPARIN DIBANDINGKAN DENGAN FONDAPARINUX PADA PASIEN DENGAN SINDROM KORONER AKUT
| Main Author: | Candradewi, SUSAN FITRIA |
|---|---|
| Format: | Thesis NonPeerReviewed |
| Terbitan: |
[Yogyakarta] : Universitas Gadjah Mada
, 2015
|
| Subjects: | |
| Online Access: |
https://repository.ugm.ac.id/134796/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=77943 |
Daftar Isi:
- Acute coronary syndromes ( ACS ) caused by an imbalance between oxygen supply and oxygen demand by the myocardium. Anticoagulants therapy is recommended and is the mainstay of therapy in patients with acute cardiovascular disease . This research aims to compare the effectiveness and costs in patients using enoxaparin and fondaparinux in patients with acute coronary syndromes . This study is a non - experimental cohort using retrospective medical record data RS.Bethesda Yogyakarta . The subjects of the study in which patients with acute coronary syndrome who received therapy enoxaparin and fondaparinux from January 2012 until December 2013.The effectiveness of therapy visits by the absence of myocardial infarction , ischemic repetitive , and death . Drug safety seen by the absence of major and minor bleeding . Cost analysis is done by calculating the cost of total therapy for patients hospitalized for . The number of patients who did not undergo myocardial infarction in group enoxaparin 17 patients ( 39.5 % ) , and 22 patients ( 78.6 % ) in group fondaparinux ( p = 0.006 , OR = 0.221 , 95 % CI = 0.073 to 0.667 ) . The difference in the number of patients who did not experience recurrent ischemic ie 34 patients in group enoxaparin , and 25 patients in the fondaparinux group ( p = 0.980 ; OR = 1.020 ; 95 % CI = 0.209 to 4.969 ) , and the number of patients who did not experience death is 37 ( 97.4 % ) , 28 ( 100 % ) ( p = 0.387 ; OR = 0.569 ; 95 % CI = 0.461 to 0.703 ) . occurrence minor bleeding in the enoxaparin and fondaparinux group of 35 ( 92.1 % ) , and 28 ( 100 % ) ( p = 0.128 ; OR = 0.556 ; 95 % CI 0.445 to 0.693 ) . effectiveness based on clinical outcomes absence of infarction was no significant difference , whereas the absence of ischemic and death is no different . security fondaparinux better than enoxaparin average total cost of the enoxaparin and fondaparinux group Rp 7073735.5 ± 4.051 million ) and Rp5,531,455.33 ± 1.915 million ) ( p = 0.161 ) . The total cost of therapy in fondaparinux more low compared to enoxaparin . The conclusion of this study is the effectiveness of enoxaparin and fondaparinux Similarly, the risk of bleeding in the lower fondaparinux , and costs fondaparinux therapy at a lower total.